Overview

• US medical device maker's fiscal 2026 revenue more than doubled, driven by LungFit PH demand

• Fiscal 2026 net loss and operating loss missed analyst expectations

• Company guides for 15% revenue growth in calendar 2026, over 110% growth in 2027

Outlook

• Beyond Air sees calendar 2026 revenue at $8 mln, up 15% from prior year

• Company expects 2027 revenue of $16-$18 mln, driven by LungFit PH commercial launch

• Beyond Air says expanding market access and international growth support revenue outlook

Result Drivers

• LUNGFIT PH DEMAND - Revenue growth was driven by increased demand for LungFit PH in the U.S. and international markets

• DISTRIBUTION EXPANSION - Expanded global distribution network for LungFit PH to more than 45 countries, positioning for further international commercial expansion

• GROUP PURCHASING AGREEMENT - Awarded a national group purchasing agreement for inhaled nitric oxide therapy with a leading U.S. group purchasing organization, expanding access to healthcare providers

Company press release: ID:nGNX1gdvQN

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY EPS		-$4.01
FY Net Income	Miss	-$34.33 mln	-$30.17 mln (3 Analysts)
FY Operating Income	Miss	-$29.04 mln	-$28.50 mln (3 Analysts)
FY Gross Profit		$252,000
FY Operating Expenses		$29.30 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Beyond Air Inc is $5.00, about 947.6% above its June 25 closing price of $0.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.